Actinogen Medical Limited (AU:ACW) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical has launched a key phase 2b/3 trial for its Alzheimer’s treatment, Xanamem, with the first US participant now enrolled. This study aims to evaluate the drug’s impact on cognitive and functional measures in patients, with interim results expected in 2025 and final results in 2026. The trial, expanding across 25 sites in the US and Australia, showcases Actinogen’s dedication to advancing innovative treatments for neurological conditions.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.